Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer

NCT01956812 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

334

Enrollment

INDUSTRY

Sponsor class

Stopped The DSMB conducted an interim analysis on overall survival, which showed that the treatment arm did not demonstrate a sufficient improvement in OS vs. placebo.

Conditions

Metastatic Pancreatic Cancer
Pancreatic Cancer

Interventions

DRUG: IMMU-107
DRUG: placebo
DRUG: Gemcitabine

Sponsor

Gilead Sciences